"Latest MS News: EBV, DMT Discontinuation, and Treatment Updates"
Research presented at the joint meeting of ECTRIMS and ACTRIMS suggests that a combination of faulty immune regulation, genetics, and specific strains of the Epstein-Barr virus (EBV) may increase the risk of developing MS. Stopping disease-modifying therapy (DMT) can lead to new disease activity, as shown in a study that had to be ended early due to participants experiencing increased disease activity. Encouraging treatment reports include the potential of foralumab to ease brain inflammation in secondary progressive MS, fenebrutinib's ability to reduce new inflammatory lesions in relapsing MS, and ongoing efforts to find ways to curb MS progression.
